RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.

@article{Yin2013RG7212AM,
  title={RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.},
  author={Xuefeng Yin and Leopoldo L. Luistro and Hua Zhong and Melissa Smith and Tom Nevins and Kathleen J Schostack and Holly Hilton and Tai-An Lin and Theresa Truitt and Denise Biondi and Xiaoqian Wang and Kathryn Packman and Jim Rosinski and Windy Berkofsky-Fessler and Jian-Ping Tang and Saumya Pant and David Geho and Suzana M Vega-Harring and Mark Demario and Hy Levitsky and Mary Simcox},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 20},
  pages={
          5686-98
        }
}
PURPOSE To explore the role of TWEAK in tumor growth and antitumor immune response and the activity and mechanism of RG7212, an antagonistic anti-TWEAK antibody, in tumor models. EXPERIMENTAL DESIGN TWEAK-induced signaling and gene expression were explored in tumor cell lines and inhibition of these effects and antitumor efficacy with RG7212 treatment was assessed in human tumor xenograft-, patient-derived xenograft, and syngeneic tumor models and phase I patients. Genetic features correlated… CONTINUE READING
Tweets
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-6 of 6 citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

A first-in-human phase I monotherapy study of RG7212, a novel monoclonal antibody targeting TWEAK signaling in patients with advanced solid tumors

  • U Lassen, D Meulendijks, LL Siu, D Jonker, M Sorensen, JHM Schellens
  • Eur J Cancer ;48:12
  • 2012
Highly Influential
4 Excerpts